

**IN THE CLAIMS**

Please cancel withdrawn Claims 59 – 91 and 95 - 131. No previously presented examined Claims are amended, and no new claims are advanced.

1-58. (Cancelled).

59 – 91 (Cancel)

92. (Cancelled)

93. (Previously Presented) A method of inhibiting human immunodeficiency virus (HIV) particle generation comprising administering to cells suspected of being infected with HIV an amount of a compound which inhibits binding between tumor susceptibility gene (TSG101) protein and HIV Gag polypeptide, wherein said compound is a peptide comprising a PTAP motif.

94. (Previously Presented) The method of Claim 93, wherein said peptide administration is effective in reducing the amount of HIV particles generated in said cells by at least two-fold, as compared with the number of particles generated in said cells in the absence of said peptide.

95 – 131 (Cancel).

132. (Previously Presented) The method of Claim 93, wherein said peptide comprises

the amino acid sequence of SEQ ID. No. 4.

133. (Previously Presented) The method of Claim 93, wherein said peptide interferes with binding between said TSG101 and said HIV Gag by inhibiting interaction in the p6 region of Gag.

134. (Previously Presented) The method of Claim 93, wherein said peptide binds to TSG101, and thereby inhibits binding of HIV Gag to TSG101, in the N-terminal E2-like (UEV) domain of TSG101.